 come along next weekend, Xolos are bound to secure their berth in the liguilla. Tijuana and Leon tied 1-1 on Saturday.
What was your favorite goal of Week 16? Any we missed? Let us know in the comments below!<gh_stars>1-10
package com.equipmentrestrictor;

import net.runelite.client.RuneLite;
import net.runelite.client.externalplugins.ExternalPluginManager;

public class EquipmentRestrictorPluginTest
{
	public static void main(String[] args) throws Exception
	{
		ExternalPluginManager.loadBuiltin(EquipmentRestrictorPlugin.class);
		RuneLite.main(args);
	}
}Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial

Background GSK’s varicella vaccine contains human serum albumin (HSA) which is used to stabilize the virus and prevent immunogens from adhering to the injection vial walls. However, because HSA is derived from human blood, there is a theoretical risk that it might contain infectious agents which could be unsafe for humans. Given this concern, a study was undertaken to compare the immunogenicity and safety of a new formulation without HSA with the currently licensed varicella vaccine in the Czech Republic and Hungary. Methods Healthy children aged 11–21 months received two doses of the varicella vaccine either with or without HSA. Antibody titres against varicella-zoster virus (anti-VZV) were measured 42 days after each dose, using an immunofluorescence assay (IFA, cut-off = 4dilution−1) and enzyme linked immunosorbent assay (ELISA, cut-off = 25 mIU/ml). Solicited local symptoms were recorded during a 4-day post-vaccination follow-up period; solicited general and unsolicited symptoms were recorded during a 43-day post-vaccination follow-up period and serious adverse event (SAEs) were recorded throughout the study. Results Of 244 children (mean age = 15.2 months [SD = 3.2]) vaccinated in the study, 233 (vaccine without HSA N = 117; vaccine containing HSA N = 116) formed the according-to-protocol immunogenicity cohort. Observed seroconversion/seroresponse rates were >98 and 100 %, 42 days after doses 1 and 2, respectively. The rates were within the same range in both groups, irrespective of the testing assay. The varicella vaccine without HSA was non-inferior to the licensed vaccine in terms of anti-VZV antibody Geometric Mean Titre/Concentration ratio (1.12 [95 % CI:0.86–1.46] by IFA; 1.12 [95 % CI:0.93–1.33] by ELISA) approximately six weeks after the first dose of the 2-dose vaccination course. The incidence of solicited and unsolicited symptoms was similar after both vaccines; low-grade fever was numerically higher after the first dose of the varicella vaccine without HSA. Seven SAEs were reported, none of which were fatal or considered to be vaccine-related. Conclusions The first dose of a new varicella vaccine without HSA was immunologically non-inferior to the licensed varicella vaccine. After two doses, both vaccines had acceptable safety profiles in children aged 11–21 months in the Czech Republic and Hungary. Trial registration NCT00568334, registered on 5 December 2007 (www.clinicaltrials.gov).


Background
In children, primary infection with varicella-zoster virus (VZV) causes chicken pox [1], a highly contagious but mostly benign disease. It can, however, be associated with a range of serious complications such as secondary bacterial infections, pneumonia, cerebellar ataxia, encephalitis and Reye's syndrome [1]. In adolescents and adults, primary VZV infection causes greater morbidity and mortality [2]. Following primary VZV infection, the latent virus persists in the central nervous system and can be reactivated in later life to cause herpes zoster (HZ) or shingles [2,3]. Complications of HZ include herpes ophthalmicus, cutaneous dissemination, pneumonia and other central nervous system, pulmonary, hepatic and pancreatic complications [4].
Two monovalent varicella vaccines are currently available in Europe: Varilrix™ (GSK Vaccines) and Varivax™ (Merck & Co. Inc), both of which are derived from the Japanese Oka strain. Placebo-controlled clinical trials have demonstrated that both vaccines are immunogenic, safe and efficacious [13,14]. A recent observer-blind study in Europe showed 65.4 % efficacy for one varicella vaccine dose at preventing confirmed varicella of any severity, and 90.7 % efficacy at preventing moderate to severe cases during 3 years of follow-up [15].
HSA is incorporated in live, attenuated vaccines to stabilize the virus and prevent immunogens from adhering to the walls of the injection vial. However, because HSA is a protein derived from human blood, there is a theoretical risk that it might contain infectious agents [26] which could make it unsafe for humans. Given this concern, the manufacturing process has been modified to remove HSA from the vaccine stabilizer added towards the end of production. This is in line with the European Medicines Agency recommendation to eliminate all blood-derived products of human origin from vaccine manufacturing [27]. This study was therefore undertaken to confirm that the varicella vaccine without HSA was immunologically non-inferior to the licensed varicella vaccine. The safety profile of both vaccines was also assessed despite the process change.

Study design and subjects
This phase II, non-inferiority study was conducted at 14 centres (offices of primary care physicians and general practitioners) in the Czech Republic (2 centres) and Hungary (12 centres) between November 2007 and April 2008 (NCT00568334). The primary care physicians recruited children and depending on the centre, either the physician/nurse administered the vaccine. The study was carried out in a double-blind manner, meaning that the investigators, study staff and parents/guardians of children were unaware of the vaccine given.
Healthy children 11-21 months of age were enrolled and randomized (1:1) to receive either two doses of varicella vaccine without HSA (Group A) or two doses of varicella vaccine containing HSA, Varilrix™ (Group B) which is licensed for the prevention of varicella in healthy children from 9 months of age. The selection criteria in this study were similar to previous studies conducted with the licensed vaccine [28,29]. The two doses were administered 42-56 days apart. Children were excluded from the study if they had received any live attenuated viral routine vaccines or investigational drug/vaccine within 30 days or immunosuppressant/immune modifying drugs/blood-derived products within six months of receiving the study vaccine. They were also excluded if they had been previously exposed to VZV or had: any confirmed or suspected immunosuppressive condition; a family history of immunodeficiency; chronic illnesses, allergies to any vaccine components or an acute disease at the time of enrolment. In order to account for the multiple routine vaccinations recommended at this age, children were allowed to receive routine inactivated vaccines up to eight days before each study vaccination so as to not interfere with the reactogenicity assessment after varicella vaccination. It was advised that children participating in the study should avoid the use of aspirin for six weeks after vaccination as Reye's syndrome has been reported following the use of aspirin during natural varicella infection.
All study-related documents including the study protocol were reviewed and approved by the Pardubice Regional Hospital and the Regional Hospital Nachod for the two participating centres, respectively, in the Czech Republic and by the Egészségügyi Tudományos Tanács Klinikai Farmakológiai Etikai Bizottság for the 14 participating centres in Hungary. The study was conducted in accordance with Good Clinical Practice, the Declaration of Helsinki and all applicable regulatory requirements. Parents/guardians provided written informed consent before any study procedures were performed.

Study vaccines
Both varicella vaccines were developed and manufactured by GSK Vaccines, Belgium. The potency of the Oka/RIT strain in the licensed varicella vaccine was 10 4.4 plaque forming units (pfu)/0.5 mL compared with 10 4.3 pfu/0.5 mL in the formulation without HSA. Both vaccines were presented as lyophilized pellets, which were reconstituted with the supplied diluent before subcutaneous injection in the left upper arm.

Safety
Parents/guardians used diary cards to record solicited local and general symptoms and unsolicited adverse events. Solicited local symptoms around the injection site (pain, redness and swelling) were recorded for four days after each dose and solicited general symptoms (fever [axillary temperature ≥37.5°C/rectal temperature ≥38°C] and rash/exanthema) were recorded for 43 days after each dose. Body temperature was measured daily via the rectal/ axillary route for eight days after each vaccine dose. Between days 8-42, the presence of fever was monitored using a temperature-sensitive forehead thermometer (FeverScan™, LCR Hallcrest, UK). If the forehead thermometer indicated fever, temperature was accurately measured using a thermometer and recorded.
The intensity of solicited symptoms